Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma

The primary goal of the trail was to determine the efficacy of combining Gemcitabine and Docetaxel in treatment of metastatic colorectal cancer with CHFR and/or Microsatellite Instability (MSI) phenotype.

本试验的首要目标是明确吉西他滨（Gemcitabine）与多西他赛（Docetaxel）联合用药，针对携带CHFR及/或微卫星不稳定性（Microsatellite Instability, MSI）表型的转移性结直肠癌的治疗疗效。